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Abstract
Reference intervals for clinical laboratory parameters are important for assessing eligibility,
toxicity grading and management of adverse events in clinical trials. Nonetheless, haemato-
logical and biochemical parameters used for clinical trials in sub-Saharan Africa are typically
derived from industrialized countries, or from WHO references that are not region-specific.
We set out to establish community reference values for haematological and biochemical
parameters amongst children aged 4 weeks to 17 months in Kilifi, Kenya. We conducted a
cross sectional study nested within phase II and III trials of RTS, S malaria vaccine candi-
date. We analysed 10 haematological and 2 biochemical parameters from 1,070 and 423
community children without illness prior to experimental vaccine administration. Statistical
analysis followed Clinical and Laboratory Standards Institute EP28-A3c guidelines. 95%
reference ranges and their respective 90% confidence intervals were determined using
non-parametric methods. Findings were compared with published ranges from Tanzania,
Europe and The United States. We determined the reference ranges within the following
age partitions: 4 weeks to <6 months, 6 months to less than <12 months, and 12 months to
17 months for the haematological parameters; and 4 weeks to 17 months for the biochemi-
cal parameters. There were no gender differences for all haematological and biochemical
parameters in all age groups. Hb, MCV and platelets 95% reference ranges in infants largely
overlapped with those from United States or Europe, except for the lower limit for Hb, Hct
and platelets (lower); and upper limit for platelets (higher) and haematocrit(lower). Commu-
nity norms for common haematological and biochemical parameters differ from developed
countries. This reaffirms the need in clinical trials for locally derived reference values to
detect deviation from what is usual in typical children in low and middle income countries.
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Introduction
In clinical trials, reference values for clinical laboratory parameters are important for screening
for eligibility; diagnosis and grading of toxicities; and management of adverse events. The ref-
erence ranges and toxicity grading scales for haematological and biochemical parameters typi-
cally used for clinical trials in sub-Saharan Africa are usually derived from industrialized
countries or from WHO references that are not region-specific [1–5]. However, typical labora-
tory parameters in communities may vary based on race, age, gender, diet, local disease pat-
terns and environmental characteristics [6–11].
An upsurge of clinical trials in developing countries in the recent years has led to questions
over the use of external references, and the need to determine what is ‘normal’ in local com-
munities in order to be able to interpret eligibility for representative participation in trials and
potential adverse events [4, 12–14]. ‘Normal’ may not be ‘optimal’, thus the target population
who may ultimately receive an intervention that is being tested may have characteristics that
fall outside international reference values when in their usual state of health [15, 16]. More-
over, available reference data may not adequately cover the youngest age groups, be gender-
specific, or may have been determined using older instruments or when characteristics of the
population and interventions such as bed net distribution or micronutrient supplementation
may have been different [17–20].
Reference intervals for biological parameters are usually defined as values falling within two
standard deviations (95% prediction) of the mean found in healthy populations [21]. The US-
based Clinical Laboratory and Standards Institute (CLSI) guidelines recommend that laborato-
ries establish their reference intervals for their own population, or validate those obtained
from a different setting [22, 23].
Adult populations in Africa often have lower haemoglobin, red blood cell counts, ha-
ematocrit, mean corpuscular volume, platelets and neutrophils, and higher monocyte and
eosinophil counts than Caucasian populations [3, 8, 24]. Creatinine and transaminases are
generally comparable to that of Caucasians [16, 23, 24]. Similarly, studies in African children
have typically shown that red blood cell parameters such as haemoglobin, haematocrit and
mean corpuscular volume are lower than those of Caucasians, with the exception of platelets
[25, 26] and eosinophils, which tend to be higher, the latter being attributed to helminth
infestation.
The aim of this study was to establish age-specific haematological and biochemistry refer-
ence values for typical children aged 4 weeks to 17 months living in Kilifi County in rural
Kenya who participated in malaria vaccine trials [27, 28].
Methods
Study site
The study took place in Kilifi district (now part of Kilifi County), Kenya, latitude -3.63, longi-
tude 39.85 degrees [29]. It is a predominantly rural area and the majority of the inhabitants are
subsistence farmers from the Mijikenda ethnic group. The staple diet is corn meal, cassava and
local green vegetables. The main income generating activities are tourism, small-scale trading,
farming, fishing and employment in nearby towns [30]. The climate is tropical with long rains
being between April to July and short rains between October and December. There has been a
downward trend of malaria prevalence locally and reduction in the densities of the major
malaria vectors, with a shift from human to animal feeding [31, 32].
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Study participants
We carried out a cross sectional study nested within phase IIb [27] and phase IIIb [28] RTS,S
malaria candidate vaccine trials. Further information on trial design and methodology can be
found in the primary trial publications [27, 28].
A series of public meetings were held in the study communities and parents who showed
interest in the study were invited to bring their children for further examination at the study
dispensary. Parents/guardians gave written consent for their children to be enrolled into these
trials and only children who were judged to have no serious acute or chronic illness as deter-
mined by history and physical examination (defined as not having any signs and symptoms of
disease, ambulatory (children older than 1 year) and not underweight, defined as weight-for-
age Z score (WAZ)-2), medical history records or laboratory screening tests were eligible.
Other exclusion criteria included a history of allergic reactions, a history of a previous blood
transfusion, major congenital defects, or a confirmed or suspected immunodeficiency disorder
(e.g. active HIV disease of Stage III or Stage IV severity, as defined by the World Health Orga-
nization, at the time of screening). There was no routine testing for HIV in the trials.
Blood samples from eligible children were then obtained before immunisation for haema-
tology (for both trials), and creatinine and alanine transaminase (only for the phase IIb trial).
We only used laboratory results taken at baseline (the screening results), prior to the adminis-
tration of trial interventions which may have otherwise influenced physiological parameters.
The only haematology parameter that was consistently done for all participants was haemoglo-
bin. Children with severe anemia, defined as a haemoglobin concentration <5.0g/dL or a hae-
moglobin concentration <8.0g/dL associated with clinical signs of heart failure or severe
respiratory distress were then excluded.
A total of 450 children aged 5–17 months were recruited between March 2007 and August
2007 in the phase IIb trial and a further 904 children were recruited 2009 to 2014 in the phase
IIIb trial in two age cohorts: 5–17 months (N = 600), and 6 to 12 weeks (N = 304).
Blood collection
Capillary and venous samples were collected from finger pricks or the antecubital fossa veins
respectively. Infants more frequently had capillary sampling due to feasibility. Samples were
collected in a 0.5 ml di-potassium ethylene diamine tetra acetic acid (K2EDTA) tube for hae-
matology and 1ml serum separator tube (SST) tube for biochemistry. Blood samples were
transported in cool boxes containing ice packs within four hours of collection to the KEMRI/
Wellcome Trust Clinical Trials Laboratory. All samples were collected in the morning hours
before midday and processed within 6 hours of collection.
Laboratory analysis
Haematological parameters examined were haemoglobin (Hb), haematocrit (Hct), mean
corpuscular haemoglobin concentration (MCHC), mean corpuscular volume (MCV), plate-
lets, white blood count (WBC) and differentials (neutrophils, lymphocytes, monocytes, eosino-
phils, and basophils) using a Beckman Coulter AcT 5 Diff Haematology Analyzer (Beckman
Coulter, USA) [33]. The biochemical parameters were alanine transaminase (ALT) and creati-
nine (Cr), analysed using a Vitalab Selectra-E clinical chemistry analyser (Vital Scientific
(Merck), Netherlands).
Normal and abnormal controls were run daily and no analysis was done if controls were
out of range. Assays were done according to manufacturer’s instructions and established stan-
dard operating procedures. The KEMRI/Wellcome Trust Clinical Trials Laboratory is a mem-
ber of two external quality assurance schemes; United Kingdom’s National External Quality
Young children reference intervals in Kilifi, Kenya
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Assessment Service (since 2003) and the Royal College of Pathologist of Australasia–Quality
Assurance Program (since 2006); and is also Good Clinical Laboratory Practice (GCLP)
accredited by Qualogy Limited since 2006.
Statistical methods
Data were double-entered to an OpenClinica1 database from source documents. Data analy-
sis was carried out using Stata 12 (Stata Corp, College Park, TX, USA) and all statistical tests
considered significant at P<0.05 (two-sided). To obtain the reference ranges we followed the
Clinical and Laboratory Standards Institute (CLSI) 2008 guidelines (EP28-A3c) [34]. CLSI rec-
ommends a minimum of 120 samples for analysis by nonparametric methods for each parti-
tion (e.g. gender, age range).
The sample population was stratified by gender and categorized into the following precon-
ceived age groups; 4 weeks to less than 6 months, 6 months to less than 12 months and 12
months to 17 months. We computed 95% reference ranges, and the 90% confidence limits
around each of the upper and lower reference values. Statistical differences by gender were
assessed using a Wilcoxon rank-sum test.
For haematology and biochemical variables, we assessed and excluded outlying values in
the analysis using Tukey’s method [35], as recommended by CLSI for establishing reference
intervals [34, 36] where there are multiple outliers. It comprises calculating the interquartile
range (IQR) for each age group, then the lower and upper boundaries were computed as fol-
lows; a) lower boundary = 25th percentile– 1.5IQR and b) upper boundary = 75th percentile
+ 1.5IQR. Any data points that were outside the lower and upper boundaries were considered
outliers and excluded from the ranges.
For comparison with other published reference ranges from Tanzania and European/
American children [26, 37], the 90% ranges for lower and upper 95% reference limit were
computed for each parameter for ages 1 to 12 months. Tanzania and European/American chil-
dren 95% lower and upper reference limits were considered not comparable if not within the
Kenyan 90% ranges. To compare to our 95% reference ranges, we estimated the means and
standard deviation using the number of participants and the 95% reference values, then used
one sample t-tests[38]. We could only compare children aged< 1year because this was the age
group with available published data.
Ethical considerations
The study protocols of the original vaccine trials were approved by the Kenya Medical
Research Institute Ethics Review Committee and regulatory approval was obtained from the
Expert Committee on Clinical Trials of the Pharmacy and Poisons Board. The studies were
conducted according to the study protocols, Declaration of Helsinki, the International Confer-
ence on Harmonization’s Good Clinical Practice standards and the Kenyan regulatory require-
ments. This secondary analysis was approved by the sponsor, the Malaria Vaccine Initiative
(MVI), and the Kenya Medical Research Institute Ethics Review Committee.
Results
There were baseline laboratory results available for a total of 1,294 enrolled subjects: 423 (33%)
from the phase IIb trial and 871 (67%) from the phase III trial. Data from 61 (4.7%) partici-
pants were excluded because they were outside the target age range. A further 163 (13%) were
excluded because they were underweight (WAZ <-2). Among the 1070 participants included
in analysis, 450(42%) were female, the median age was 8.2 (IQR 3.2–12.5) months, the median
WAZ was -0.54 (IQR -1.18 to 0.12).
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For haematology values, results from 1,070 children from both trials were included. Bio-
chemical values were only obtained during the phase IIb RTS,S trial and 381 results were ana-
lysed (Fig 1).
The 95% reference ranges and the 90% confidence intervals for the upper and lower limits
for the red blood cell indices and platelet counts; white blood cell and chemistry parameters
are displayed in Tables 1, 2 and 3 respectively. The 95% reference ranges for creatinine and
ALT for 4 weeks to 17 month old children were 26.5 to 45.0 μmol/L and 9.0 to 34.0 IU/L
respectively (Table 3).
There were no statistically significant differences by gender for all assessed haematological
and biochemical parameters (S1 Table, S2 Table and S3 Table).
Reference haematological values for Tanzanian and European/American infants were
examined for comparison (Tables 4 and 5 and S4 Table). We did not find appropriate pub-
lished reference intervals covering 4 weeks to 17 months of age to compare with our biochemi-
cal parameters.
Discussion
We have established a set of haematological and biochemistry reference intervals representa-
tive of non-underweight children without identified acute or chronic illness aged between 4
Fig 1. Participant flow diagram.
https://doi.org/10.1371/journal.pone.0177382.g001
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weeks to 17 months living in rural Kilifi County. The results describe what is typical in the
population, rather than what is optimally healthy.
There was no evidence of gender differences for all haematological and biochemical param-
eters (see S1, S2 and S3 Tables). This is consistent with previous studies that showed that gen-
der differences for most haematological and chemistry parameters start being evident during
adolescence [39–42].
Differences in haematological values among different populations have been attributed to
factors such as nutrition, genetic differences, exposure to infectious diseases, environmental
factors and socio-economic status. Despite Kenya and Tanzania being neighbouring countries
in East Africa, our 2.5th percentile for Hb and Hct; and the 97.5th percentile for WBC, neutro-
phils, lymphocytes, and basophils were lower than those for Tanzanian children [26]. The 2.5th
percentile platelet counts, WBC and monocytes were higher than those for Tanzanian chil-
dren. The 97.5th percentile platelet counts, monocytes and eosinophils were higher than those
for Tanzanian children. Overall, these results suggest that anaemia and inflammation are more
common in Kilifi, Kenya than in the Kilimanjaro Region, Tanzania. The 2.5th percentile for
neutrophils, lymphocytes, basophils and MCV; and the 97.5th percentile of Hb and Hct were
comparable (Table 5 and S4 Table).
Table 1. 95% reference ranges with 90% confidence intervals for selected haematological parameters for Kilifi children aged 1–17 months.
Parameter/Age group N* 95% Reference
range
90% Confidence interval (Lower reference
limits)
90% Confidence interval (Upper reference
limits)
Haemoglobin (g / dl)
1 to 6 months 358 8.1–13.8 7.6–8.4 13.6–14.1
6 to 12 months 386 7.0–11.5 6.9–7.3 11.4–11.8
12 to 17 months 306 7.1–11.9 6.9–7.5 11.6–12.1
Overall 1050 7.2–12.7 7.0–7.5 12.6–12.9
Haematocrit (%)
1 to 6 months 299 24.8–41.9 23.8–25.7 40.9–43.2
6 to 12 months 321 23.2–36.1 22.6–23.8 35.1–36.7
12 to 17 months 222 25.0–36.6 23.4–25.6 35.7–37.1
Overall 842 23.9–38.3 23.3–24.7 37.8–38.7
MCHC (g/dL)
1 to 6 months 301 31.2–34.7 30.9–31.4 34.5–35.1
6 to 12 months 322 29.5–33.8 29.2–29.9 33.7–34.1
12 to 17 months 224 28.9–33.5 28.2–29.0 33.5–34.2
Overall 847 29.4–34.4 29.2–29.6 34.2–34.5
MCV (fl)
1 to 6 months 305 57–100 55–59 98–103
6 to 12 months 328 51–78 50–53 77–80
12 to 17 months 227 50–79 48–51 77–81
Overall 860 52–97 51–53 96–98
Platelets (×103 cells/
μL)
1 to 6 months 303 74–765 23–113 713–835
6 to 12 months 318 104–798 84–151 756–837
12 to 17 months 217 184–769 142–220 747–807
Overall 838 84–773 55–100 752–812
N* varies for each age group as some lab tests were not done for all participants and the following outliers were excluded from analysis:Hb-19, Hct-5,
MCHC-8, MCV-0, Platelets- 15.
https://doi.org/10.1371/journal.pone.0177382.t001
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Table 2. 95% reference ranges with 90% confidence intervals for selected white blood cells parameters for Kilifi children aged 1–17 months.
Parameter/Age group N* 95% reference
values
90% confidence interval (Lower reference
Limits)
90% confidence interval (Upper reference
Limits)
WBC(×103 cells/μL)
1 to 6 months 293 4.74–14.77 4.50–5.41 13.75–15.87
6 to 12 months 321 6.70–17.39 6.20–7.04 16.70–17.91
12 to 17 months 218 5.84–16.66 5.05–6.50 16.10–17.75
Overall 832 5.71–16.72 5.31–6.05 16.41–17.08
Neutrophils(×103 cells/
μL)
1 to 6 months 211 0.57–3.53 0.37–0.68 3.32–3.77
6 to 12 months 234 1.05–4.25 0.71–1.12 3.93–4.39
12 to 17 months 137 0.95–5.56 0.76–1.02 4.89–5.97
Overall 582 0.70–4.39 0.64–0.82 4.18–4.45
Lymphocytes(×103 cells/
μL)
1 to 6 months 229 3.06–9.04 2.14–3.45 8.52–9.47
6 to 12 months 237 3.38–10.97 3.06–3.71 10.83–11.35
12 to 17 months 137 2.97–9.75 2.19–3.21 9.38–10.37
Overall 603 3.13–10.20 2.99–3.39 9.87–10.77
Monocytes(×103 cells/μL)
1 to 6 months 218 0.38–1.89 0.28–0.44 1.81–1.98
6 to 12 months 234 0.60–2.06 0.51–0.65 1.96–2.17
12 to 17 months 134 0.48–1.91 0.31–0.55 1.72–1.94
Overall 586 0.48–1.93 0.43–0.52 1.91–2.01
Eosinophils(×103 cells/
μL)
1 to 6 months 211 0.07–0.70 0.05–0.11 0.61–0.78
6 to 12 months 232 0.07–1.20 0.04–0.09 1.11–1.31
12 to 17 months 134 0.05–1.20 0.03–0.08 0.99–1.28
Overall 577 0.06–0.98 0.05–0.08 0.92–1.02
Basophils(×103 cells/μL)
1 to 6 months 193 0.01–0.06 0.00–0.01 0.05–0.07
6 to 12 months 214 0.01–0.04 0.00–0.01 0.04–0.04
12 to 17 months 123 0.01–0.06 0.00–0.01 0.04–0.06
Overall 583 0.01–0.06 0.00–0.01 0.05–0.06
N* varies for each age group as some lab tests were not done for all participants and the following outliers were excluded from analysis: (WBC– 29,
Neutrophils- 31, Lymphocytes- 21, Monocytes- 27, Eosinophils- 36, Basophils- 30).
https://doi.org/10.1371/journal.pone.0177382.t002
Table 3. 95% reference ranges with 90% confidence intervals for selected biochemistry parameters for Kilifi children aged 1–17 months.
Parameter N* 95% Reference
values
90% Confidence interval (Lower reference
Limits)
90% Confidence interval (Upper reference
Limits)
Creatinine (μmol/
L)
419 27–45 25–28 44–46
ALT (IU/L) 408 9–34 7–10 32–35
N* varies for each parameter because the following outliers were excluded from analysis: ALT- 14, Cr-3.
https://doi.org/10.1371/journal.pone.0177382.t003
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Several African studies that have shown lower red blood cell indices in children and adults
[16, 24, 25, 43] compared to American or European children [37]; we also observed this for
Hb, Hct and MCV(Table 5 and S4 Table). This may be attributed to several factors that are
common in the community, including malaria, other parasitic infestations [44, 45], haemoglo-
binopathies [46] and iron deficiency anaemia [47].
The 2.5th and 97.5th percentile platelet counts in children from Kilifi indicated values that
would be classified as thrombocytopenia and thrombocytosis respectively if evaluated by refer-
ence ranges among European/American populations. However, they were not associated with
clinical features. This was also observed amongst Tanzanian children (Table 5 and S4 Table).
Thrombocytopenia can result from impaired platelet production, increased platelet destruc-
tion (immune and non–immune) and abnormal vascular distribution e.g. splenic sequestra-
tion. One potential cause of thrombocytopenia in African populations is P. falciparum malaria
[48, 49].
Thrombocytosis may be attributed to persistent elevated thrombopoetin levels observed in
iron deficiency [50] or inflammation that stimulates its production in the liver [51]. Chronic
Table 4. 95% reference intervals for selected haematological parameters: Kenyan infants aged 1 to less than 12 months (current study), compared
to published data from Tanzania and United States/Europe.
Kenya (current study) *Tanzania
(2010)
*US/Europe
(2006)
Parameter Lower 95%
reference value
90% Confidence interval
for lower reference value
Upper 95%
reference value
90% Confidence interval
for upper reference value
95% Reference
ranges
95% Reference
ranges
Haemoglobin
(g/dl)
7.3 7.0–7.6 13.2 12.9–13.5 8.1–13.2 9.4–13.0
Haematocrit
(%)
23.5 22.9–24.3 39.2 38.6–39.9 25.1–38.6 28–42
MCV (fl) 53.4 52.2–55.0 98.6 97.0–99.3 53.3–96.6 70–98
Platelets (103/
μL)
72.7 51.5–89.6 769.2 738.4–822.8 25–708 150–400
*References: Tanzanian data (Buchanan et al. 2010) and USA/European data (Simpkin & Hinchliffe 2006).
https://doi.org/10.1371/journal.pone.0177382.t004
Table 5. 95% reference intervals for white blood cell counts for Kenyan infants aged 1 to less than 12 months, compared to published data from
Tanzania and United States/Europe.
Kenya (current study) *Tanzania
(2010)
*US/Europe
(2006)
Parameter Lower 95%
reference value
90% Confidence interval
for lower reference value
Upper 95%
reference value
90% Confidence interval
for upper reference value
95% Reference
ranges
95% Reference
ranges
WBC (x103 cells/
μL)
5.6 5.2–5.9 16.6 16.2–16.9 2.0–17.3 5.0–17.0
Neutrophils (x103
cells/μL)
0.7 0.6–0.8 4.1 3.9–4.2 0.7–4.6 0.7–8.0
Lymphocytes
(x103 cells/μL)
3.3 2.9–3.5 10.2 9.9–10.8 3.3–11.8 3.3–11.5
Monocytes (x103
cells/μL)
0.5 0.42–0.53 2.0 1.9–10.8 0.2–1.5 0.2–1.3
Eosinophils (x103
cells/μL)
0.06 0.05–0.08 0.9 0.8–1.0 0.1–0.8 0.05–1.1
Basophils (x103
cells/μL)
0.01 0.01–0.01 0.07 0.06–0.08 0.01–0.14 0.02–0.13
*References: Tanzanian data (Buchanan et al. 2010) and USA/European data (Simpkin & Hinchliffe 2006).
https://doi.org/10.1371/journal.pone.0177382.t005
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inflammation is commonly the result of environmental enteric dysfunction, associated with
poor sanitation resulting in gut infections, malabsorption and malnutrition [52, 53]. These
findings accord with recent studies indicating that platelet counts may be higher in African
paediatric populations compared to Caucasian populations [26, 43, 54, 55].
The WBC 2.5th and 97.5th percentiles were higher and lower respectively than those for
Tanzanian and American/European populations. Other African studies have shown that the
WBC counts in infants tend to be similar or lower than those of Caucasians [26, 43]. The 2.5th
percentile for eosinophils was comparable to that of American/European populations while
the 97.5th percentile was comparable with for Tanzania (Table 5 and S4 Table).
The 97.5th percentile for neutrophils was higher in the European/American infants com-
pared to our study (Table 5 and S4 Table), as other African studies have demonstrated [26, 43,
56]. This may due to sub-clinical infection. This has also been attributed to a regulatory variant
in the Duffy antigen receptor for chemokines [56].
Eosinophils had a lower upper limit in Kilifi when compared to European/American
infants, but higher than those for Tanzanian children (Table 5 and S4 Table). Some studies
have shown that eosinophils tend to be elevated in African populations due to environmental
factors such as helminthiasis [43].
The monocyte 95% intervals were comparable for both Tanzanian and European/American
populations, while Kilifi had a higher lower and upper limit (Table 5 and S4 Table). Monocytes
have been shown to play an important role in immune mechanisms against protozoal infec-
tions such as malaria, with elevated monocytes levels being observed in malaria endemic set-
tings [57–59]. The study area is malaria endemic and this might have contributed to higher
monocyte count compared to Tanzanian and European/American infants.
Strengths and limitations
The major strength of the study is that we analysed a large sample (>1000) of children in a
community setting at the time of recruitment for a clinical trial. We believe our reference
ranges are representative of typical community children in similar settings in Africa who
would ultimately benefit from successful trials. Our study had a number of limitations. Screen-
ing could not conclusively rule out all forms of illness such as parasitic infestations, sickle cell
anaemia, thalassaemia and micronutrient deficiencies that may have affected the parameters.
The HIV status of the children was also not assessed, but in apparently healthy children HIV
prevalence would be expected to be less than 1%. The reference ranges are therefore represen-
tative of children in the community without acute illness who would typically be eligible for
clinical trials, rather than intended to define a state of optimal health. There was no suitable
study to compare our biochemistry results with. Because of sample size, biochemistry results
were not partitioned by age groups.
Conclusion
This study, like others in Africa, has shown that commonly used European/American refer-
ence ranges do not well suit typical African populations. This reaffirms the need for locally-
derived reference values for clinical research in order to appropriately assign eligibility and
interpret adverse events.
Supporting information
S1 Table. 95% reference ranges with 90% confidence intervals for selected haematological
parameters for Kilifi children aged 1–17 months stratified by gender.
(PDF)
Young children reference intervals in Kilifi, Kenya
PLOS ONE | https://doi.org/10.1371/journal.pone.0177382 May 11, 2017 9 / 13
S2 Table. 95% reference ranges with 90% confidence intervals for selected white blood cells
parameters for Kilifi Children aged 1–17 months stratified by gender.
(PDF)
S3 Table. 95% reference ranges with 90% confidence intervals for selected biochemistry
parameters for Kilifi Children aged 1–17 months stratified by gender.
(PDF)
S4 Table. Selected haematological parameters for Kenyan infants aged 1 to less than 12
months, compared to published data from Tanzania and United States/Europe.
(PDF)
Acknowledgments
We would like to thank the study participants who took part in the two RTS,S trials. PATH—
Malaria Vaccine Initiative (MVI) gave us permission to use their data. Permission to submit
the manuscript for publication was given by the Director, Kenya Medical Research Institute.
Author Contributions
Conceptualization: JG PA PN RC JAB.
Data curation: CO CK MN GF GN TO GM KA BL.
Formal analysis: JG CO MN GF JAB.
Funding acquisition: PN AO RC.
Investigation: JG CO CK PA PN AO GN TO GM KA BL.
Methodology: JG CO MN PN RC JAB.
Project administration: JG CO MN PN RC.
Resources: PN RC BL.
Software: MN GF.
Supervision: RC JAB.
Validation: MN GF JAB.
Visualization: JG CO MN PN RC JAB.
Writing – original draft: JG CO.
Writing – review & editing: JG CO MN CK PA PN GN TO GM KA BL RC JAB.
References
1. WHO. Haemoglobin concentrations for the diagnosis of anaemia and assessment of severity.July 12,
2014. Available from: http://www.who.int/vmnis/indicators/haemoglobin.pdf.
2. Syndrome DoAI. The Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse
Events.2004. Available from: http://www.niaid.nih.gov/LabsAndResources/resources/DAIDSClinRsrch/
Documents/daidsaegradingtable.pdf.
3. Clement E. Zeh COOaLAM. Laboratory Reference Intervals in Africa. September 21, 2012 [cited 16th
July,2014]. In: Blood Cell—An Overview of Studies in Hematology [Internet]. InTech, [cited 16th
July,2014]; [18].
Young children reference intervals in Kilifi, Kenya
PLOS ONE | https://doi.org/10.1371/journal.pone.0177382 May 11, 2017 10 / 13
4. Lusingu J, Olotu A, Leach A, Lievens M, Vekemans J, Olivier A, et al. Safety of the malaria vaccine can-
didate, RTS,S/AS01E in 5 to 17 month old Kenyan and Tanzanian Children. PLoS One. 2010; 5(11):
e14090. Epub 2010/12/03. PubMed Central PMCID: PMC2993932. https://doi.org/10.1371/journal.
pone.0014090 PMID: 21124768
5. WHO. Haemoglobin concentrations for the diagnosis of anaemia and assessment of severity.: Vitamin
and Mineral Nutrition Information System. Geneva, World Health Organization, 2011.; 2011. Available
from: http://www.who.int/vmnis/indicators/haemoglobin.
6. Vincent-Viry M, Fournier B, Gueguen R, Henny J, Monneau JP, Siest G. Biochemical values of immi-
grant groups in north-east France. Ann Hum Biol. 1990; 17(4):277–87. Epub 1990/07/01. PMID:
2393252
7. Tsegaye A, Messele T, Tilahun T, Hailu E, Sahlu T, Doorly R, et al. Immunohematological reference
ranges for adult Ethiopians. Clin Diagn Lab Immunol. 1999; 6(3):410–4. Epub 1999/05/04. PubMed
Central PMCID: PMC103732. PMID: 10225845
8. Tugume SB, Piwowar EM, Lutalo T, Mugyenyi PN, Grant RM, Mangeni FW, et al. Hematological refer-
ence ranges among healthy Ugandans. Clin Diagn Lab Immunol. 1995; 2(2):233–5. Epub 1995/03/01.
PubMed Central PMCID: PMC170134. PMID: 7697535
9. Rustad P, Felding P, Franzson L, Kairisto V, Lahti A, Martensson A, et al. The Nordic Reference Interval
Project 2000: recommended reference intervals for 25 common biochemical properties. Scand J Clin
Lab Invest. 2004; 64(4):271–84. Epub 2004/06/30. https://doi.org/10.1080/00365510410006324 PMID:
15223694
10. Obeid R, Geisel J, Schorr H, Hubner U, Herrmann W. The impact of vegetarianism on some haematolo-
gical parameters. Eur J Haematol. 2002; 69(5–6):275–9. Epub 2002/12/04. PMID: 12460231
11. Leon-Velarde F, Gamboa A, Chuquiza JA, Esteba WA, Rivera-Chira M, Monge CC. Hematological
parameters in high altitude residents living at 4,355, 4,660, and 5,500 meters above sea level. High Alt
Med Biol. 2000; 1(2):97–104. Epub 2001/03/21. https://doi.org/10.1089/15270290050074233 PMID:
11256567
12. Maiga D, Akanmori BD, Chocarro L. Regulatory oversight of clinical trials in Africa: progress over the
past 5 years. Vaccine. 2009; 27(52):7249–52. Epub 2009/09/15. https://doi.org/10.1016/j.vaccine.
2009.08.113 PMID: 19748580
13. Lang T, Siribaddana S. Clinical trials have gone global: is this a good thing? PLoS Med. 2012; 9(6):
e1001228. Epub 2012/06/22. PubMed Central PMCID: PMC3373653. https://doi.org/10.1371/journal.
pmed.1001228 PMID: 22719228
14. Maitland K, Kiguli S, Opoka RO, Engoru C, Olupot-Olupot P, Akech SO, et al. Mortality after fluid bolus
in African children with severe infection. N Engl J Med. 2011; 364(26):2483–95. Epub 2011/05/28.
https://doi.org/10.1056/NEJMoa1101549 PMID: 21615299
15. Omosa-Manyonyi GS, Jaoko W, Anzala O, Ogutu H, Wakasiaka S, Malogo R, et al. Reasons for ineligi-
bility in phase 1 and 2A HIV vaccine clinical trials at Kenya AIDS vaccine initiative (KAVI), Kenya. PLoS
One. 2011; 6(1):e14580. Epub 2011/02/02. PubMed Central PMCID: PMC3024980. https://doi.org/10.
1371/journal.pone.0014580 PMID: 21283743
16. Karita E, Ketter N, Price MA, Kayitenkore K, Kaleebu P, Nanvubya A, et al. CLSI-derived hematology
and biochemistry reference intervals for healthy adults in eastern and southern Africa. PLoS One. 2009;
4(2):e4401. Epub 2009/02/07. PubMed Central PMCID: PMC2632744. https://doi.org/10.1371/journal.
pone.0004401 PMID: 19197365
17. Schnabl K, Chan MK, Gong Y, Adeli K. Closing the gaps in paediatric reference intervals: the CALIPER
initiative. The Clinical biochemist Reviews / Australian Association of Clinical Biochemists. 2008; 29
(3):89–96. Epub 2008/12/25. PubMed Central PMCID: PMC2605413.
18. Adeli K. Closing the gaps in pediatric reference intervals: An Update on the CALIPER Project. Clinical
biochemistry. 2014; 47(9):737–9. Epub 2014/05/27. https://doi.org/10.1016/j.clinbiochem.2014.05.037
PMID: 24858208
19. Allen LH. Interventions for micronutrient deficiency control in developing countries: past, present and
future. J Nutr. 2003; 133(11 Suppl 2):3875S–8S.
20. Bhatt S, Weiss DJ, Cameron E, Bisanzio D, Mappin B, Dalrymple U, et al. The effect of malaria control
on Plasmodium falciparum in Africa between 2000 and 2015. Nature. 2015; 526(7572):207–11.
PubMed Central PMCID: PMCPMC4820050. https://doi.org/10.1038/nature15535 PMID: 26375008
21. Ceriotti F, Hinzmann R, Panteghini M. Reference intervals: the way forward. Annals of clinical biochem-
istry. 2009; 46(Pt 1):8–17. https://doi.org/10.1258/acb.2008.008170 PMID: 19103955
22. Defining, Establishing, and Verifying Reference Intervals in the Clinical Laboratory; Approved Guideli-
ne.2008Wayne, PA: Clinical and Laboratory Standards Institute.October 27, 2013; 28.
Young children reference intervals in Kilifi, Kenya
PLOS ONE | https://doi.org/10.1371/journal.pone.0177382 May 11, 2017 11 / 13
23. Zeh C, Amornkul PN, Inzaule S, Ondoa P, Oyaro B, Mwaengo DM, et al. Population-based biochemis-
try, immunologic and hematological reference values for adolescents and young adults in a rural popu-
lation in Western Kenya. PLoS One. 2011; 6(6):e21040. Epub 2011/06/30. PubMed Central PMCID:
PMC3119664. https://doi.org/10.1371/journal.pone.0021040 PMID: 21713038
24. Kibaya RS, Bautista CT, Sawe FK, Shaffer DN, Sateren WB, Scott PT, et al. Reference ranges for the
clinical laboratory derived from a rural population in Kericho, Kenya. PLoS One. 2008; 3(10):e3327.
Epub 2008/10/04. PubMed Central PMCID: PMC2553265. https://doi.org/10.1371/journal.pone.
0003327 PMID: 18833329
25. Odutola AA, Afolabi MO, Jafali J, Baldeh I, Owolabi OA, Owiafe P, et al. Haematological and biochemi-
cal reference values of Gambian infants. Tropical medicine & international health: TM & IH. 2014; 19
(3):275–83.
26. Buchanan AM, Muro FJ, Gratz J, Crump JA, Musyoka AM, Sichangi MW, et al. Establishment of hae-
matological and immunological reference values for healthy Tanzanian children in Kilimanjaro Region.
Tropical medicine & international health: TM & IH. 2010; 15(9):1011–21. Epub 2010/07/20. PubMed
Central PMCID: PMC3024440.
27. Olotu A, Lusingu J, Leach A, Lievens M, Vekemans J, Msham S, et al. Efficacy of RTS,S/AS01E
malaria vaccine and exploratory analysis on anti-circumsporozoite antibody titres and protection in chil-
dren aged 5–17 months in Kenya and Tanzania: a randomised controlled trial. The Lancet infectious
diseases. 2011; 11(2):102–9. Epub 2011/01/18. PubMed Central PMCID: PMC3341451. https://doi.
org/10.1016/S1473-3099(10)70262-0 PMID: 21237715
28. Rts SCTP Agnandji ST, Lell B, Fernandes JF, Abossolo BP Methogo BG, et al. A phase 3 trial of RTS,
S/AS01 malaria vaccine in African infants. The New England journal of medicine. 2012; 367(24):2284–
95. Epub 2012/11/10. https://doi.org/10.1056/NEJMoa1208394 PMID: 23136909
29. Spraggs C, McCarthy A, McCarthy L, Hong G, Hughes A, Lin X, et al. Genetic variants in the epithelial
sodium channel associate with oedema in type 2 diabetic patients receiving the peroxisome proliferator-
activated receptor gamma agonist farglitazar. Pharmacogenet Genomics. 2007; 17(12):1065–76.
https://doi.org/10.1097/FPC.0b013e3282f1b2d7 PMID: 18004211
30. Marsh VM, Kamuya DM, Mlamba AM, Williams TN, Molyneux SS. Experiences with community
engagement and informed consent in a genetic cohort study of severe childhood diseases in Kenya.
BMC medical ethics. 2010; 11:13. Epub 2010/07/17. PubMed Central PMCID: PMC2918624. https://
doi.org/10.1186/1472-6939-11-13 PMID: 20633282
31. Mwangangi JM, Mbogo CM, Orindi BO, Muturi EJ, Midega JT, Nzovu J, et al. Shifts in malaria vector
species composition and transmission dynamics along the Kenyan coast over the past 20 years.
Malaria journal. 2013; 12:13. PubMed Central PMCID: PMC3544599. https://doi.org/10.1186/1475-
2875-12-13 PMID: 23297732
32. Okiro EA, Hay SI, Gikandi PW, Sharif SK, Noor AM, Peshu N, et al. The decline in paediatric malaria
admissions on the coast of Kenya. Malaria journal. 2007; 6:151. PubMed Central PMCID:
PMC2194691. https://doi.org/10.1186/1475-2875-6-151 PMID: 18005422
33. Pickett JA, Birkett MA, Bruce TJ, Chamberlain K, Gordon-Weeks R, Matthes MC, et al. Developments
in aspects of ecological phytochemistry: the role of cis-jasmone in inducible defence systems in plants.
Phytochemistry. 2007; 68(22–24):2937–45. https://doi.org/10.1016/j.phytochem.2007.09.025 PMID:
18023830
34. CLSI.Defining, Establishing, and Verifying Reference Intervals in the Clinical Laboratory; Approved
Guideline—Third Edition.CLSI document EP28-A3c. Wayne, PA: Clinical and Laboratory Standards
Institute; 2008
35. Tukey JW. Exploratory Data Analysis. Reading, MA: Addison-Wesley; 1977:688.
36. Dixon WJ. Processing Data for Outliers. Biometrics. 1953; 9:74–89.
37. Simpkin P & Hinchliffe RF (2006) Reference values. In: Pediatric Hematology, 3rd edn. (eds Arceci R,
Hann IM & Smith OP) Blackwell Publishing Ltd, Oxford, UK, pp. 792–810.
38. Cochrane Handbook for Systematic Reviews of Interventions. Available from: http://handbook.
cochrane.org/chapter_7/7_7_3_2_obtaining_standard_deviations_from_standard_errors_and.htm.
39. Gomez P, Coca C, Vargas C, Acebillo J, Martinez A. Normal reference-intervals for 20 biochemical vari-
ables in healthy infants, children, and adolescents. Clin Chem. 1984; 30(3):407–12. Epub 1984/03/01.
PMID: 6697487
40. Burritt MF, Slockbower JM, Forsman RW, Offord KP, Bergstralh EJ, Smithson WA. Pediatric reference
intervals for 19 biologic variables in healthy children. Mayo Clinic proceedings. 1990; 65(3):329–36.
Epub 1990/03/01. PMID: 2314122
41. Yip R, Johnson C, Dallman PR. Age-related changes in laboratory values used in the diagnosis of ane-
mia and iron deficiency. The American journal of clinical nutrition. 1984; 39(3):427–36. Epub 1984/03/
01. PMID: 6695842
Young children reference intervals in Kilifi, Kenya
PLOS ONE | https://doi.org/10.1371/journal.pone.0177382 May 11, 2017 12 / 13
42. Castro OL, Haddy TB, Rana SR. Age- and sex-related blood cell values in healthy black Americans.
Public health reports. 1987; 102(2):232–7. Epub 1987/03/01. PubMed Central PMCID: PMC1477821.
PMID: 3104982
43. Lugada ES, Mermin J, Kaharuza F, Ulvestad E, Were W, Langeland N, et al. Population-based hemato-
logic and immunologic reference values for a healthy Ugandan population. Clin Diagn Lab Immunol.
2004; 11(1):29–34. Epub 2004/01/13. PubMed Central PMCID: PMC321349. https://doi.org/10.1128/
CDLI.11.1.29-34.2004 PMID: 14715541
44. Ashford RW, Craig PS, Oppenheimer SJ. Polyparasitism on the Kenya coast. 1. Prevalence, and asso-
ciation between parasitic infections. Annals of tropical medicine and parasitology. 1992; 86(6):671–9.
Epub 1992/12/01. PMID: 1304710
45. Brooker S, Peshu N, Warn PA, Mosobo M, Guyatt HL, Marsh K, et al. The epidemiology of hookworm
infection and its contribution to anaemia among pre-school children on the Kenyan coast. Transactions
of the Royal Society of Tropical Medicine and Hygiene. 1999; 93(3):240–6. Epub 1999/09/24. PMID:
10492749
46. Williams TN, Weatherall DJ. World distribution, population genetics, and health burden of the hemoglo-
binopathies. Cold Spring Harbor perspectives in medicine. 2012; 2(9):a011692. Epub 2012/09/07.
https://doi.org/10.1101/cshperspect.a011692 PMID: 22951448
47. Atkinson SH, Armitage AE, Khandwala S, Mwangi TW, Uyoga S, Bejon PA, et al. Combinatorial effects
of malaria season, iron deficiency, and inflammation determine plasma hepcidin concentration in Afri-
can children. Blood. 2014; 123(21):3221–9. PubMed Central PMCID: PMCPMC4046425. https://doi.
org/10.1182/blood-2013-10-533000 PMID: 24596418
48. Pukrittayakamee S, White NJ, Clemens R, Chittamas S, Karges HE, Desakorn V, et al. Activation of the
coagulation cascade in falciparum malaria. Transactions of the Royal Society of Tropical Medicine and
Hygiene. 1989; 83(6):762–6. PMID: 2482560
49. Gerardin P, Rogier C, Ka AS, Jouvencel P, Brousse V, Imbert P. Prognostic value of thrombocytopenia
in African children with falciparum malaria. The American journal of tropical medicine and hygiene.
2002; 66(6):686–91. PMID: 12224575
50. Schafer AI. Thrombocytosis. The New England journal of medicine. 2004; 350(12):1211–9. https://doi.
org/10.1056/NEJMra035363 PMID: 15028825
51. Wolber EM, Fandrey J, Frackowski U, Jelkmann W. Hepatic thrombopoietin mRNA is increased in
acute inflammation. Thrombosis and haemostasis. 2001; 86(6):1421–4. PMID: 11776309
52. Crane RJ, Jones KD, Berkley JA. Environmental enteric dysfunction: an overview. Food Nutr Bull.
2015; 36(1 Suppl):S76–87. PubMed Central PMCID: PMCPMC4472379. https://doi.org/10.1177/
15648265150361S113 PMID: 25902619
53. Campbell DI, Murch SH, Elia M, Sullivan PB, Sanyang MS, Jobarteh B, et al. Chronic T cell-mediated
enteropathy in rural west African children: relationship with nutritional status and small bowel function.
Pediatr Res. 2003; 54(3):306–11. https://doi.org/10.1203/01.PDR.0000076666.16021.5E PMID:
12788978
54. Humberg A, Kammer J, Mordmuller B, Kremsner PG, Lell B. Haematological and biochemical reference
intervals for infants and children in Gabon. Tropical medicine & international health: TM & IH. 2011; 16
(3):343–8. Epub 2011/01/05.
55. Kumwenda NI, Khonje T, Mipando L, Nkanaunena K, Katundu P, Lubega I, et al. Distribution of haema-
tological and chemical pathology values among infants in Malawi and Uganda. Paediatrics and interna-
tional child health. 2012; 32(4):213–27. Epub 2012/11/21. PubMed Central PMCID: PMC3571100.
https://doi.org/10.1179/2046905512Y.0000000034 PMID: 23164296
56. Reich D, Nalls MA, Kao WH, Akylbekova EL, Tandon A, Patterson N, et al. Reduced neutrophil count in
people of African descent is due to a regulatory variant in the Duffy antigen receptor for chemokines
gene. PLoS genetics. 2009; 5(1):e1000360. Epub 2009/01/31. PubMed Central PMCID: PMC2628742.
https://doi.org/10.1371/journal.pgen.1000360 PMID: 19180233
57. Lunel F, Druilhe P. Effector cells involved in nonspecific and antibody-dependent mechanisms directed
against Plasmodium falciparum blood stages in vitro. Infection and immunity. 1989; 57(7):2043–9.
PubMed Central PMCID: PMCPMC313839. PMID: 2659533
58. Tebo AE, Kremsner PG, Luty AJ. Plasmodium falciparum: a major role for IgG3 in antibody-dependent
monocyte-mediated cellular inhibition of parasite growth in vitro. Experimental parasitology. 2001; 98
(1):20–8. https://doi.org/10.1006/expr.2001.4619 PMID: 11426948
59. Manson’s Tropical Diseases. 22nd ed. UK: Saunders Ltd; 2009. 1800 p.
Young children reference intervals in Kilifi, Kenya
PLOS ONE | https://doi.org/10.1371/journal.pone.0177382 May 11, 2017 13 / 13
